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Abstract
Background: Despite new therapeutic approaches have improved the prognosis of newborns with retinopathy of
prematurity (ROP), an unfavourable structural and functional outcome still remains high. There is high pressure to
develop new drugs to prevent and treat ROP. There is increasing enthusiasm for anti-VEGF drugs, but angiogenic
inhibitors selective for abnormal blood vessels would be considered as an optimal treatment.
In an animal experimental model of proliferative retinopathy, we have recently demonstrated that the pharmacological
blockade of beta-adrenoreceptors improves retinal neovascularization and blood retinal barrier breakdown consequent
to hypoxia. The purpose of this study is to evaluate the propranolol administration in preterm newborns suffering from
a precocious phase of ROP in terms of safety and efficacy in counteracting the progression of retinopathy.
Methods/Design: Preterm newborns (gestational age at birth lower than 32 weeks) with stage 2 ROP (zone II-III
without plus) will be randomized, according to their gestational age, to receive propranolol added to standard
treatment (treatment adopted by the ETROP Cooperative Group) or standard treatment alone. Propranolol will be
administered until retinal vascularization will be completely developed, but not more than 90 days. Forty-four
participants will be recruited into the study. To evaluate the safety of propranolol administration, cardiac and
respiratory parameters will be continuously monitored. Blood samplings will be performed to check renal, liver and
metabolic balance. To evaluate the efficacy of propranolol, the progression of the disease, the number of laser
treatments or vitrectomies, the incidence of retinal detachment or blindness, will be evaluated by serial
ophthalmologic examinations. Visual function will be evaluated by means of behavioural standardized tests.
Discussion: This pilot study is the first research that explores the possible therapeutic role of beta blockers in ROP.
The objective of this research is highly ambitious: to find a treatment simple, inexpensive, well tolerated and with
few adverse effects, able to counteract one of the major complications of the prematurity. Any favourable results
of this research could open new perspectives and original scenarios about the treatment or the prevention of this
and other proliferative retinopathies.
Trial Registration: Current Controlled Trials ISRCTN18523491; ClinicalTrials.gov Identifier NCT01079715; EudraCT
Number 2010-018737-21.
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Background
The retinopathy of prematurity
A. Disease incidence
Retinopathy of prematurity (ROP) is a major cause of
blindness and visual impairment in children in both
developing and developed countries around the world,
despite of progressive improvements in neonatal care
[1]. The overall incidence of any ROP in the USA varies
from 65 [2] to 68% [3] among infants with a birth
weight less than 1,250 g. However, the overall incidence
of more-severe ROP (prethreshold), a condition that can
lead to retinal detachment and blindness, is progres-
sively increased to around thirty-seven percent among
infants with ROP in the ETROP Study [3]. The inci-
dence of this disease is closely related to the birth
weight and the gestational age at birth: the lower the
birth weight and earlier postconceptional age at birth,
the higher the likelihood of developing a more severe
disease. However, preterm infants developing severe
ROP in middle and low income countries have a wider
range of birth weights and gestational ages than what is
usually observed in industrialized countries [1].
B. Disease pathogenesis
ROP is a multifactorial neovascularizing disease that
affects premature infants, characterized by perturbation
of the normal vascular development of the retina. In the
human fetus, retinal blood vessel development begins
during the fourth month of gestation, and this process
usually occurs in the hypoxic uterine environment.
Therefore, in very premature infants, the retina is nearly
avascular at birth, and premature birth usually stops the
process of retinal vascular development that normally
occurs in the hypoxic uterine environment [4].
The pathogenesis of ROP is hypothesized to consist
of two distinct phases [5]. The exposure to extra-
uterine relative hyperoxia amplified by supplemental
oxygen delivery retards or blocks the normal retinal
vascular growth (first phase of ROP), decreasing the
Vascular Endothelial Growth Factor (VEGF) expression
and endothelial cell proliferation [6]. The loss of pla-
centa contributes to reduce the vascularization of
retina due to the reduction of the Insulin-like Growth
Factor-1 (IGF-1) levels (largely produced by the pla-
centa) [7]. Therefore, this first phase of ROP is charac-
terized by cessation of vessel growth and loss of
vessels.
The second phase of ROP begins at 32-34 weeks of post-
menstrual age, and is characterized by a hypoxia-induced
retinal neovascularization similar to that observed in other
proliferative retinopathies such as diabetic retinopathy or
age-related macular degeneration [4].
The shift to this proliferative phase of ROP is usually
explained by the imbalance between the poorly developed
blood vessels and the increasing metabolic demands of
developing neural retina. This imbalance produces retinal
hypoxia, that increases the stability of inducible a subunit
of the transcription factor hypoxia-inducible factor
(HIF)-1. HIF-1a accumulation leads to the subsequent
transactivation of HIF which, in turn, upregulates the
expression of a variety of genes including those encoding
for angiogenic growth factors [8]. Among them, VEGF,
IGF-1, and their receptors induce a pathological blood
vessel formation at the junction between the vascularized
retina and the avascular zone of the retina, also into the
vitreous. Progressively, this pathological neovasculariza-
tion produces a fibrous scar extending from the retina to
the vitreous gel and lens, the retraction of which can
separate the retina from the retinal pigment epithelium,
resulting in a retinal detachment and likely blindness [4].
However this explanation of the shift from the first to
the second phase of ROP is rather indefinite. All contri-
butions capable to better explain this transition could
have important implications for the understanding and
treatment of ROP.
C. VEGF in retinopathy of prematurity
Oxygen tension plays a key role in VEGF expression.
Hyperoxia decreases VEGF levels, and this phenomenon
has been hypothesized to play a key role in the first
stage of ROP. Precocious exposure to extra-uterine rela-
tive hyperoxia, as observed in premature newborns,
results in suppression of VEGF expression, increased
apoptosis and vasoattenuation [9,10].
Instead, hypoxia is the driving force for blood vessel
growth, through the increase in VEGF gene expression
[11-13], as observed during the second phase of ROP,
which is a proliferative phase.
VEGF is now considered essential in driving the devel-
opment and growth of blood vessels [14]. Increased
VEGF expression is seen in Müller cells and astrocytes of
the inner retina during the development of neovasculari-
zation [15], and an increase in VEGF receptors is
observed in the vicinity of target endothelial cells [16,17].
VEGF is overexpressed in response to hypoxia and ische-
mia. As hypoxia is relieved by oxygen release from the
newly formed vessels, then VEGF overexpression is dras-
tically reduced. VEGF stimulates its receptor VEGFR-2
and induces endothelial cell cytoprotection through the
activation of the protein kinase B (PKB)/Akt pathway
[18], whereas the stimulation of mitogen-activated pro-
tein kinase (MAPK) cascade by VEGF/VEGFR-2 pro-
motes the proliferation of endothelial cells [19].
D. Role of IGF-1
In mice, IGF-1 is critical for physiological development
of retinal vessels: the lack of IGF-1 in IGF-1 knockout
mice, in fact, depresses blood vessel development,
despite the presence of VEGF [20].
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Low levels of IGF-1 prevent VEGF-induced activation
of PKB/Akt, a critical kinase for endothelial cell survival
[20]. In premature newborns, levels of IGF-1 have been
reported to be low, as a consequence of loss of the pla-
centa, and ROP risk has been associated with low circu-
lating levels of IGF-1 [21]. In fact serial measurements of
serum IGF-1 levels in preterm newborns have demon-
strated that IGF-1 levels are inversely correlated with the
severity of clinical ROP [7,21,22]. Low levels of IGF-1
compromised both endothelial cell survival and prolifera-
tion pathways. These data suggest that low IGF-1 levels
could contribute to the vessels degeneration typical of
the first phase of ROP [21].
However, IGF-1 also plays an important role also in
the proliferative phase of ROP. With maturation, IGF-1
increases slowly, reaching a threshold level at around 34
weeks of gestational age. Then, IGF-1 promotes VEGF-
induced neovascularization, most likely through the sti-
mulation of the MAPK pathway [23].
Similarly to what observed for VEGF, the mechanism
by which IGF-1 progressively increases is, to date, still
unknown.
E. Role of oxygen
Studies in preterm infants have demonstrated a relation
between exposure to high levels of oxygen and the
development of ROP [24-27]. The high extrauterine
concentration of oxygen suppresses VEGF expression,
and this phenomenon explains the vaso-obliteration
induced by the apoptosis of vascular endothelial cells in
the first phase of ROP.
Actually, the idea that relative hypoxia of avascular
retina is responsible for the development of the second
phase of ROP could be explained by the hypoxia-driven
production of VEGF, although this mechanism does not
explain the increase of IGF-1, that is usually considered
a non-oxygen-regulated factor [7].
This theory raised the possibility that supplemental
oxygen might be used to improve retinal oxygenation
and to down-regulate retinal neovascularization. The
STOP-ROP Study has been planned to test the
hypothesis that supplemental oxygen administered to
preterm infants with pre-threshold ROP would
improve retinal oxygenation, down-regulate retinal
neovascularization, and finally reduce the progression
of ROP. However, newborns randomized to receive
oxygen to keep their oxygen saturations either 88-94%
or 96-99%, did not show any differences in the pro-
gression of ROP [28].
F. Conclusion
Until now, a clear explanation of the progression from
the first to the second phase of ROP has not been given.
Probably a better understanding of this passage may
provide new therapeutic possibilities.
G. Standard treatment of retinopathy of prematurity
The best currently available management of ROP con-
sists of the early identification of high-risk vascular pat-
tern of the developing retina (i.e., dilated venules and
tortuous arterioles at the posterior pole of the eye) at
first, and then in the laser ablation of the avascular per-
ipheral retina. Multicenter trials have indicated the man-
ner in which ROP should be monitored and treated.
The CRYO-ROP studies showed that treating threshold
diseases (stage 3 ROP in at least five contiguous or eight
non-contiguous clock hours) improved visual and struc-
tural outcomes in premature infants [29,30]. Benefits of
earlier treatment were investigated in the ETROP study
[31]. This study demonstrated that ablative therapy was
beneficial for any eye with any stage of ROP in zone I
with plus disease, stage 3 ROP in zone I with or without
plus disease, and stage 2 or 3 ROP in zone II with plus
disease [32]. The 2-year data collected in the ETROP
study showed that unfavourable structural outcomes
(defined as retinal folds or detachment) decreased in
eyes that received early ablative therapy [33]. Visual
acuity improved at 6 years of age only in newborns with
Type 1 high-risk prethreshold eyes [34] (those with plus
disease in either Zone I or Zone II, or Zone I stage 3
disease) [32]. Long-term structural and functional out-
comes suggest that laser photocoagulation is superior to
cryotherapy [35,36].
Despite these advances, the unfavourable structural
and functional outcomes still remain high, and treat-
ment with laser photocoagulation carries itself a cer-
tainty of lasting peripheral visual dysfunction.
H. Novel treatments of retinopathy of prematurity
Since ROP is a VEGF-dependent vasoproliferative dis-
ease, it is not surprising that there is increasing enthu-
siasm for anti-VEGF drugs (bevacizumab, ranibizumab)
[37-39]. Anti-VEGF drugs do not ablate retinal tissue,
and seem to be effective to counteract the abnormal
neovascularization of the ridge (the demarcation line
between vascularized and avascular retina characteristic
of stage 2 ROP). However, undesirable consequences
could be met because VEGF and its receptors play an
important role in the development of the neural retina,
and potential adverse effects of anti-VEGF drugs can
not be excluded on developing neurons in the immature
retina [4]. For instance, mice treated with specific VEGF
receptor antagonists demonstrate a cell loss in the inner
nuclear layer, containing Muller cell nuclei and in the
ganglion cell layer, containing astrocytes [40].
In addition, the dosage and the timing of injections are
still to be defined. Moreover, the incidence of complica-
tions related to the need of multiple injections including
ocular trauma or endophthalmitis, together with the sys-
temic effects of such antagonists, are still to be evaluated.
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Consequently, new pharmacological approaches for
the prevention and treatment of ROP are urgently
needed. The ideal treatment would be to find an angio-
genic inhibitor selective for abnormal blood vessels, but
this drug is yet to be developed.
I. Beta-adrenoreceptor function and vascularization
Recently, propranolol, a well-tolerated, non-selective,
beta-adrenoreceptor (beta-AR) blocker has been
reported as an effective drug in reducing the growth of
infantile hemangiomas, the most common tumour of
infancy [41]. It has been hypothesized that propranolol
may act through a reduction of VEGF levels [42].
There is some evidence that the adrenergic system is
involved in the regulation of hypoxia-induced neovascu-
larization and VEGF production. For instance, in
embryonic heart, hypoxia has been shown to cause cate-
cholaminergic overstimulation that, in turn, alters sig-
nalling pathways associated with beta-adrenoreceptors
(ARs) [43]. In addition, norepinephrine stimulates the
production of VEGF in endothelial cells of the human
umbilical vein, [44], and induces vascular VEGF gene
expression in brown adipocytes [45]. The role of the
adrenergic system in the regulation of proangiogenic
factors has also been demonstrated in solid tumours
and tumour cell lines: norepinephrine, in fact, affects
tumour progression by upregulating VEGF through the
beta2-AR stimulation. This proangiogenic effect is antag-
onized by propranolol [46-54].
Beta2-ARs are widely expressed on vascular endothe-
lial cells [55], and an interesting study provided evidence
that beta2-ARs can regulate neoangiogenesis in response
to chronic ischemia. In fact, in the endothelium of the
rat femoral artery, ischemia produces a beta2-ARs over-
expression on endothelial cells promoting VEGF pro-
duction, cell proliferation, and function including
revascularization. This observation suggests a novel and
physiologically relevant role of beta2-ARs in neoangio-
genesis in response to ischemia [56].
Considering that beta2-AR stimulation upregulates
VEGF, and that the second phase of ROP is supported
by an increased VEGF production, we hypothesized that
VEGF overexpression in ROP could be induced by
beta2-ARs stimulation, and that beta-blockers could be
useful in the treatment of ROP (Figure 1). This hypoth-
esis was supported by the observation that infantile
hemangiomas are associated with the development of
ROP in infants, suggesting a possible pathogenic rela-
tionship between the two diseases [57].
Beta-AR expression in the retina has been established
at both the messenger and the protein level [58]. In addi-
tion, distinct beta-ARs have been localized in cultured
retinal endothelial cells, Muller cells and retinal pigment
epithelium [59-62]. Little is known about beta-AR locali-
zation and function in the retina [61,63]. Beta3-AR
activation has been reported to cause proliferation and
migration of retinal endothelial cells [59]. In addition, in
human choroidal endothelial cells, the beta-AR agonist
isoproterenol leads to increased level of growth factors
implicated in ocular diseases [60].
J. New research perspectives derived from recent studies on
oxygen-induced retinopathy model
Recently we tested the role of the adrenergic system in a
mouse model of oxygen-induced retinopathy (OIR) [64],
considering that this animal model is characterized by
the abnormal formation of new blood vessels which can
be assimilated to ROP [65]. We investigated the role of
propranolol in regulation of retinal angiogenesis and
vascular permeability. More specifically, we determined
whether propranolol affects retinal levels of proangio-
genic factors, vascular leakage and retinal neovasculari-
zation. The mechanisms of action of propranolol on
angiogenesis were also investigated.
We demonstrated that, in OIR mice, the retinal
expression of HIF-1a significantly increased (about 7.5
fold), as compared to control littermates. Hypoxia upre-
gulated VEGF, VEGF receptor 1 (VEGFR-1), VEGF
receptor 2 (VEGFR-2), IGF-1 and IGF-1 receptor (IGF-
1R) messengers as well as VEGF protein. Moreover,
hypoxia increased beta3-AR protein with dense beta3-
AR-immunoreactivity localized to engorged retinal tufts.
Treatment with propranolol partially restored the
hypoxia-induced increase in IGF-1 mRNA and VEGF
mRNA. Hypoxic levels of VEGF protein were dose-
dependently reduced by propranolol, without affecting
those of VEGFR-1, VEGFR-2 and IGF1-R mRNAs.
Mechanisms coupling beta-AR blockade with VEGF
inhibition included an important role of the transcrip-
tion factor HIF-1a, which was consistently reduced by
propranolol, indicating that HIF-1a is likely to partici-
pate in the mechanisms coupling beta-AR blockade with
VEGF inhibition. The additional finding that the IGF1-R
antagonist picropodophyllin to propranolol-treated mice
did not affect the propranolol-induced inhibition of ret-
inal VEGF suggests that propranolol effects on VEGF
did not involve IGF-1 signalling, although IGF-1 is a
potent inducer of VEGF.
The pharmacological blockade of beta-ARs interferes
with retinal neovascularization through propranolol-
induced downregulation of proangiogenic factors. In
fact, in our study, propranolol drastically reduced retinal
haemorrhages and tufts, improved the retinopathy score,
partially restored the levels of the tight junction protein
occludin and decreased extravascular leakage of albu-
min. The efficacy of propranolol in reducing the
hypoxia-induced blood retinal barrier breakdown was
finally confirmed with the Evan’s blue method [66].
Propranolol reduced VEGF overproduction in the
hypoxic retina, but did not affect the VEGF levels in the
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Figure 1 Beta2-adrenoreceptors stimulation and ROP: role of propranolol in pharmacological blockade of abnormal
neovascularization. Red arrows show the likely effects of propranolol.
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normoxic retina, suggesting different pattern of regula-
tion of VEGF transcriptional pathways in normoxic and
hypoxic conditions. This possibility is supported by the
additional finding that beta-AR blockade does not influ-
ence VEGF levels in the brain, lungs or heart in which
VEGF expression is not regulated by hypoxia, indicating
that these organs probably do not experience hypoxia in
the OIR model. These data also suggest that only the
VEGF produced under hypoxia-ischemia (most likely
induced through the HIF-1a stimulation) can be
affected by the inhibition of beta-ARs.
Moreover, we demonstrated that propranolol did not
reduce vascular hyperpermeability induced by intravi-
treal injection of exogenous VEGF. This finding suggests
that propranolol does not influence the VEGF-induced
downstream signalling pathways, consistent with the
result that the expression of VEGF receptors is not
changed after propranolol treatment [66].
These results provide the first demonstration that
beta-ARs are coupled with a modulation of VEGF and
IGF-1 in the OIR model and suggest a role of catechola-
mines in the shift from the first to the second phase of
ROP. The hypothesis on which we are currently working
on, is that in this animal model the chronic ischemia
induces an overexpression of beta3-ARs on vascular
endothelial cells, which in turn could stimulate the acti-
vation (cross-talk) of beta2-ARs (data still unpublished).
Hypothesis
Our finding that in mice hypoxic retinas propranolol
downregulates proangiogenic factors, improves the
proangiogenic effect of hypoxia, and repairs at least in
part the hypoxia-induced blood retinal barrier break-
down is particularly intriguing in light of a possible
therapeutic use of beta-AR blockers to counteract ret-
inal neovascularization in ROP.
Our hypothesis is that also in human preterm new-
borns with ROP, VEGF overexpression could be induced
by beta2-AR stimulation, and that propranolol, a well-
tolerated, non-selective, beta-AR blocker, administered
in preterm newborns when a precocious phase of ROP
is detected, could reduce the progression of the disease.
Objectives
Major objectives: safety and efficacy of propranolol
Propranolol in children is considered safe and generally
well tolerated. Nevertheless, the possibility of some side
effects has to be considered. Reported side effects are
usually mild and transient, and include bronchospasm,
heart failure, prolonged hypoglycaemia, bradycardia,
heart block [67]. Such problems have also been observed
also in newborns [68,69], but they may be clinically rele-
vant in unstable preterm newborns.
The main purpose of this study is to evaluate the
safety of propranolol administration in such premature
newborns. To evaluate its safety, cardiac and respiratory
parameters (heart frequency, blood pressure, oxygen
saturation, respiratory support), will be continuously
monitored. Blood samplings will be performed to check
renal, liver and metabolic balance.
Further objective of this study is to evaluate the effi-
cacy of propranolol to reduce the progression of ROP,
the incidence of either retinal detachment or blindness,
through serial ophthalmologic examinations, planned at
different intervals according to the severity of ROP, in
comparison with what observed in a control group
receiving conventional treatment (treatment adopted by
the ETROP Cooperative Group).
All newborns will be evaluated at 40 weeks of gesta-
tional age by using a recently published battery of beha-
vioural tests designed to assess various aspects of visual
function [70], which includes items that assess ocular
movements (spontaneous behaviour and in response to
a target), the ability to fix and follow a black/white tar-
get (horizontally, vertically, and in an arc), the reaction
to a coloured target, the ability to discriminate between
black and white stripes of increasing spatial frequency,
and the ability to keep attention on a target that is
moved slowly away from the infant. Visual function will
be evaluated again at 1, 4 1/2, 12, 18 and 24 months
corrected age [71] with particular regards to visual
acuity (binocular and monocular), measured by means
of well known instruments based on preferential force
choice (Teller acuity cards), stereopsis and ocular
motricity.
Secondary objectives
1) plasma propranolol concentration will be determined
through serial measurements on dried blood spots, to
characterize its pharmacokinetic profile in relation to
the clinical effects of the therapy. In the recent years the
use of dried blood spot (DBS) technology to obtain
pharmacokinetic data has increased [72,73]. DBS sam-
pling has many advantages, which include reducing the
volume of blood required from patients such as new-
borns with limited available quantity of blood. Other
advantages include a less invasive sampling method, and
easy, and cheap sample collection, transportation, and
storage.
2) plasma concentrations of proangiogenic markers
will be determined in premature newborns treated with
propranolol and compared with those measured in pre-
mature infants with standard treatment, to investigate
whether propranolol decreases their plasma levels. The
aim is to evaluate the efficacy of propranolol in regulat-
ing the plasma levels of VEGF, the soluble forms of the
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tyrosine kinase receptors, sVEGFR-2 and sTie-2 and
sE-selectin, an inducible endothelial leukocyte adhesion
molecule expressed on the surface of endothelial cells
[74,75].
Methods/Design
a. Study design
We planned an interventional pilot randomized con-
trolled trial in two-centre to compare the safety and effi-
cacy of propranolol associated to a conventional
approach (treatment adopted by the ETROP Cooperative
Group) versus conventional approach alone to treat pre-
term newborns (gestational age less than 32 weeks) with
a stage 2 ROP (zone II-III without plus). Propranolol will
be administered per os at the dose of 0.5 mg/kg/every
6 hours. The protocol provides that ophthalmologists
will be blindfolded about which newborns will be treated
with propranolol in addition to conventional approach.
b. Experimental plan and data analysis
Based on the medical literature, the percentage of stage
2 ROP that progresses to more-severe ROP is around
36% [3]. We hypothesized that treatment with proprano-
lol may be able to block the progression of this disease
and therefore that the percentage of the progression to
more severe ROP may be zero. In order to compare the
proportions of newborns in propranolol group (treated)
and control group (standard treatment), that progresses
to more-severe ROP, the estimated sample size was cal-
culated, considering normal distribution, an alpha error
of 0.05 and a power of 80 percent. The sample size for
each group is 22 participants.
The incidence of progression from stage 2 ROP to
higher stages increases with the decreasing of the gesta-
tional age. To ensure a homogeneous distribution of the
gestational age in both groups (treated and controls),
the recruited newborns will be randomized and stratified
according to their gestational age in three different
groups: group 1 (23-25 weeks), group 2 (26-28 weeks),
and group 3 (29-32 weeks)
The two units have an overall admission rate of
approximately 300 very low birth weight babies per year.
Due to the high hypothetical advantages of this treat-
ment, we estimate 90-100% rate of consent and we pre-
dict we would recruit the 44 newborns over around
18 months period with a realistic safety margin.
To evaluate propranolol safety, cardiac and respiratory
parameters (heart frequency, blood pressure, oxygen
saturation, respiratory support), will be continuously
monitored. Blood samplings will be performed as soon
as the stage 2 ROP will be diagnosed, to check renal,
liver and metabolic balance. Kruskal-Wallis test will be
used to assess possible differences between newborns
treated or not with propranolol. The safety will be also
evaluated by means of relative risk (RR) [76]. RR will be
calculated as the ratio between the probability of side
effects in the propranolol group with respect to the con-
trol group.
RR will be also calculated as the ratio between the
probability that ROP progresses to more-severe ROP in
propranolol group with respect to the control group. In
this case, values of RR lower than 1, will be associated
to the efficacy of the treatment. If necessary, RR for
each gestational age group, will be obtained.
c. Allocation of participants to the trial groups
(Randomization)
Randomization will be done stratifying eligible newborns
for the gestational age (23-25, 26-28 and 29-32 weeks)
to ensure identical incidence of risk. In both recruiting
hospitals, newborns will be randomized in blocks of
eight for each gestational age group, alternating between
propranolol added to standard treatment and standard
treatment alone, where standard treatment is the treat-
ment adopted by the ETROP Cooperative Group [32].
d. Study population-setting
Preterm newborns delivered at gestational age lower
than 32 weeks admitted to the Neonatal Intensive Care
Unit at the A. Meyer University Childrens’ Hospital,
Florence and at the Institute of Pediatrics and Neonatol-
ogy, Fondazione IRCCS Ospedale Maggiore Policlinico,
Mangiagalli e Regina Elena, University of Milan.
e. Inclusion criteria
1. Preterm newborns (gestational age lower than
32 weeks) who developed stage 2 ROP (zone II-III with-
out plus).
2. Informed Consent from a parent.
f. Selection criteria for study subjects
At least one of the parents of newborns who meet the
inclusion criteria will be approached by the study inves-
tigator/nurse and informed of the study. A signed par-
ental informed consent will be obtained.
g. Exclusion criteria
1. Newborns with congenital cardiovascular anomalies,
renal failure, failure to thrive, cerebral haemorrhage,
which contraindicate the use of beta-blockers.
2. Newborns with ROP at a more advanced stage than
stage 2 (zone II-III without plus).
3. Newborns in whom propranolol administration will
be stopped for more than two doses, with the exception
of a temporary suspension before surgery.
4. Informed Consent from a parent refused.
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h. Stop criteria
The study could be stopped if severe hypotension, bra-
dycardia or bronchospasm develops; in this case, the
opportunity to reduce the dose of propranolol may be
considered.
i. Special condition
Taking into account that newborns with posthemorrha-
gic hydrocephalus usually have high levels of VEGF in
the cerebrospinal fluid [77,78], such neonates will be
enrolled, but analyzed separately.
j. Ethical approval
A two-centre phase II pilot study entitled “Safety and effi-
cacy of propranolol in newborns with Retinopathy of Pre-
maturity (PROP-ROP): a pilot study” has been approved
by the Ethics Committees of both A. Meyer University
Childrens’ Hospital, Florence and Fondazione IRCCS Cà
Granda Ospedale Maggiore Policlinico, Milan.
Informed consent will be obtained from at least one of
the parents prior to study entry. Parents will be given
full verbal and written information regarding the objec-
tive and procedures of the study and the possible risks
involved.
Propranolol is considered safe for use in children.
Nevertheless, a careful watch will be kept on all study
participants with regard to side effects of drug adminis-
tration. Parents of participants will be made aware of
possible side effects. Infants will be monitored in the
Neonatal Intensive Care Unit throughout the study per-
iod and their clinical condition will be evaluated daily as
part of medical rounds. A letter informing the partici-
pant and the family doctor as to which study arm the
participant had been randomized to will be sent follow-
ing completion of the study.
In the presence of adverse events, a reduction of
dosage will be taken into account.
For ethical and scientific reasons, an interim analysis
after the enrolment of half of the newborns, is planned.
k. Duration of the treatment
The treatment period will begin following randomiza-
tion. On day 0 baseline measurements will be taken and
recorded, and propranolol administration will be begun.
This treatment will continue until the complete develop-
ment of retinal vascularization, although this administra-
tion can not last more than 90 days.
l. Follow-up
Ophthalmologic evaluations are planned usually every
3-4 days, or more frequently according to clinical evolu-
tion and severity of ROP, until the end of the vasculari-
zation process is achieved. Ophthalmologists will be
blindfolded about which newborns have been treated
with propranolol in addition to conventional approach.
The efficacy will be evaluated comparing the different
incidences of the progression of ROP to stages 3 or to
retinal detachment, the different incidence of laser treat-
ment, the different incidence of vitrectomy, between the
two groups. To evaluate structural and functional out-
come, the follow-up is planned at 40 weeks gestational
age, 4 1/2, 12, 18 and 24 months corrected age.
m. Measurement of outcomes
1. Primary endpoint
To evaluate if the propranolol administration reduces
the percentage of progression of stage 2 ROP to more-
severe ROP from actual 36-37% [3] to zero, serial
ophthalmologic evaluations are planned at different
intervals according to the severity of ROP.
2. Secondary endpoint
a. To evaluate the safety of propranolol treatment, car-
diac and respiratory parameters (heart frequency, blood
pressure, oxygen saturation, respiratory support) will be
continuously monitored; blood samplings will be per-
formed to check renal, liver and metabolic balance; urea
plasma levels will be compared to evaluate the effect of
propranolol on whole body protein metabolism
b. To evaluate if the number of laser treatments and
vitrectomies is decreased in the newborns co-treated
with propranolol.
c. To evaluate if propranolol improves the functional
and structural outcome, visual function and ophthalmo-
logic examination are planned at 40 weeks gestational
age, 1, 4 1/2, 12, 18 and 24 months corrected age.
3. Surrogate endpoint
Plasma concentration of proangiogenic markers (VEGF,
the soluble forms of the tyrosine kinase receptors,
sVEGFR-2 and sTie-2 and sE-selectin) will be measured
in blood samples collected at randomization, before the
beginning of treatment, and weekly for the first 3 weeks
after randomization.
n. Confidentiality
The participants’ data collected during this trial will be
kept confidential. Study staff will have access to the data
as well as the participants’ medical records as they per-
tain to this study. Published results will not contain any
information that would identify individual participants.
Discussion
The objective of this research is highly ambitious: to
find a treatment simple, inexpensive, well tolerated and
with few adverse effects, able to counteract one of the
major complications of the prematurity. Our recent
findings in the animal model indicate that the use of
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propranolol is promising and that this should be
explored in human newborns. However, many uncer-
tainties remain.
Firstly, it is unknown what dose of propranolol should
be used in the newborns. We have demonstrated that,
in OIR mice, proangiogenic factors were dose-depen-
dently reduced by propranolol. We chose the dose of 2
mg/kg/day because is a low-dosage that usually does
not produce adverse effects and because at this dosage
propranolol is employed in the treatment of hemangio-
mas. However, it is likely that a higher dosage might be
more effective or that a lower dosage might be safer.
Secondly, it is currently unknown when propranolol
should be started and how long it should be adminis-
tered. Thirdly, a larger sample of patients could give
more reliable answers about the effectiveness of this
treatment.
In conclusion, this pilot study is the first research that
explores the possible therapeutic role of beta2 blockers
in ROP. Any favourable results of this research could
open new perspectives and original scenarios about the
treatment or the prevention of this and other prolifera-
tive retinopathies.
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